Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Effector Therapeutics Inc (NQ: EFTR )

0.4896 -0.0804 (-14.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Effector Therapeutics Inc

eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models 
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules 
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting
eFFECTOR to host conference call following ASCO presentation 
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer
The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers predictive... 
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI) 
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023 
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.